Protein arginine N-methyltransferase 5 in colorectal carcinoma: Insights into mechanisms of pathogenesis and therapeutic strategies

Protein arginine N-methyltransferase 5 (PRMT5) enzyme is one of the eight canonical PRMTs, classified as a type II PRMT, induces arginine monomethylation and symmetric dimethylation. PRMT5 is known to be overexpressed in multiple cancer types, including colorectal cancer (CRC), where its overexpress...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wafaa Abumustafa, Batoul Abi Zamer, Bariaa A. Khalil, Mawieh Hamad, Azzam A. Maghazachi, Jibran Sualeh Muhammad
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2022
Materias:	PRMT5 Colorectal cancer Epigenetics Histone modification Theranostics Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/b01cd0d624564e58b94a9ab843e7ab63
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b01cd0d624564e58b94a9ab843e7ab63
record_format	dspace
spelling	oai:doaj.org-article:b01cd0d624564e58b94a9ab843e7ab632021-11-18T04:43:34ZProtein arginine N-methyltransferase 5 in colorectal carcinoma: Insights into mechanisms of pathogenesis and therapeutic strategies0753-332210.1016/j.biopha.2021.112368https://doaj.org/article/b01cd0d624564e58b94a9ab843e7ab632022-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S0753332221011525https://doaj.org/toc/0753-3322Protein arginine N-methyltransferase 5 (PRMT5) enzyme is one of the eight canonical PRMTs, classified as a type II PRMT, induces arginine monomethylation and symmetric dimethylation. PRMT5 is known to be overexpressed in multiple cancer types, including colorectal cancer (CRC), where its overexpression is associated with poor survival. Recent studies have shown that upregulation of PRMT5 induces tumor growth and metastasis in CRC. Moreover, various novel PRMT5 inhibitors tested on CRC cell lines showed promising anticancer effects. Also, it was suggested that PRMT5 could be a valid biomarker for CRC diagnosis and prognosis. Hence, a deeper understanding of PRMT5-mediated CRC carcinogenesis could provide new avenues towards developing a targeted therapy. In this study, we started with in silico analysis correlating PRMT5 expression in CRC patients as a prelude to further our investigation of its role in CRC. We then carried out a comprehensive review of the scientific literature that dealt with the role(s) of PRMT5 in CRC pathogenesis, diagnosis, and prognosis. Also, we have summarized key findings from in vitro research using various therapeutic agents and strategies directly targeting PRMT5 or disrupting its function. In conclusion, PRMT5 seems to play a significant role in the pathogenesis of CRC; therefore, its prognostic and therapeutic potential merits further investigation.Wafaa AbumustafaBatoul Abi ZamerBariaa A. KhalilMawieh HamadAzzam A. MaghazachiJibran Sualeh MuhammadElsevierarticlePRMT5Colorectal cancerEpigeneticsHistone modificationTheranosticsTherapeutics. PharmacologyRM1-950ENBiomedicine & Pharmacotherapy, Vol 145, Iss , Pp 112368- (2022)
institution	DOAJ
collection	DOAJ
language	EN
topic	PRMT5 Colorectal cancer Epigenetics Histone modification Theranostics Therapeutics. Pharmacology RM1-950
spellingShingle	PRMT5 Colorectal cancer Epigenetics Histone modification Theranostics Therapeutics. Pharmacology RM1-950 Wafaa Abumustafa Batoul Abi Zamer Bariaa A. Khalil Mawieh Hamad Azzam A. Maghazachi Jibran Sualeh Muhammad Protein arginine N-methyltransferase 5 in colorectal carcinoma: Insights into mechanisms of pathogenesis and therapeutic strategies
description	Protein arginine N-methyltransferase 5 (PRMT5) enzyme is one of the eight canonical PRMTs, classified as a type II PRMT, induces arginine monomethylation and symmetric dimethylation. PRMT5 is known to be overexpressed in multiple cancer types, including colorectal cancer (CRC), where its overexpression is associated with poor survival. Recent studies have shown that upregulation of PRMT5 induces tumor growth and metastasis in CRC. Moreover, various novel PRMT5 inhibitors tested on CRC cell lines showed promising anticancer effects. Also, it was suggested that PRMT5 could be a valid biomarker for CRC diagnosis and prognosis. Hence, a deeper understanding of PRMT5-mediated CRC carcinogenesis could provide new avenues towards developing a targeted therapy. In this study, we started with in silico analysis correlating PRMT5 expression in CRC patients as a prelude to further our investigation of its role in CRC. We then carried out a comprehensive review of the scientific literature that dealt with the role(s) of PRMT5 in CRC pathogenesis, diagnosis, and prognosis. Also, we have summarized key findings from in vitro research using various therapeutic agents and strategies directly targeting PRMT5 or disrupting its function. In conclusion, PRMT5 seems to play a significant role in the pathogenesis of CRC; therefore, its prognostic and therapeutic potential merits further investigation.
format	article
author	Wafaa Abumustafa Batoul Abi Zamer Bariaa A. Khalil Mawieh Hamad Azzam A. Maghazachi Jibran Sualeh Muhammad
author_facet	Wafaa Abumustafa Batoul Abi Zamer Bariaa A. Khalil Mawieh Hamad Azzam A. Maghazachi Jibran Sualeh Muhammad
author_sort	Wafaa Abumustafa
title	Protein arginine N-methyltransferase 5 in colorectal carcinoma: Insights into mechanisms of pathogenesis and therapeutic strategies
title_short	Protein arginine N-methyltransferase 5 in colorectal carcinoma: Insights into mechanisms of pathogenesis and therapeutic strategies
title_full	Protein arginine N-methyltransferase 5 in colorectal carcinoma: Insights into mechanisms of pathogenesis and therapeutic strategies
title_fullStr	Protein arginine N-methyltransferase 5 in colorectal carcinoma: Insights into mechanisms of pathogenesis and therapeutic strategies
title_full_unstemmed	Protein arginine N-methyltransferase 5 in colorectal carcinoma: Insights into mechanisms of pathogenesis and therapeutic strategies
title_sort	protein arginine n-methyltransferase 5 in colorectal carcinoma: insights into mechanisms of pathogenesis and therapeutic strategies
publisher	Elsevier
publishDate	2022
url	https://doaj.org/article/b01cd0d624564e58b94a9ab843e7ab63
work_keys_str_mv	AT wafaaabumustafa proteinargininenmethyltransferase5incolorectalcarcinomainsightsintomechanismsofpathogenesisandtherapeuticstrategies AT batoulabizamer proteinargininenmethyltransferase5incolorectalcarcinomainsightsintomechanismsofpathogenesisandtherapeuticstrategies AT bariaaakhalil proteinargininenmethyltransferase5incolorectalcarcinomainsightsintomechanismsofpathogenesisandtherapeuticstrategies AT mawiehhamad proteinargininenmethyltransferase5incolorectalcarcinomainsightsintomechanismsofpathogenesisandtherapeuticstrategies AT azzamamaghazachi proteinargininenmethyltransferase5incolorectalcarcinomainsightsintomechanismsofpathogenesisandtherapeuticstrategies AT jibransualehmuhammad proteinargininenmethyltransferase5incolorectalcarcinomainsightsintomechanismsofpathogenesisandtherapeuticstrategies
_version_	1718425121846198272

Protein arginine N-methyltransferase 5 in colorectal carcinoma: Insights into mechanisms of pathogenesis and therapeutic strategies

Ejemplares similares